Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: A Children’s Oncology Group Report

. Author manuscript; available in PMC: 2015 Nov 1.

Published in final edited form as: Br J Haematol. 2014 Jul 26;167(3):394–401. doi: 10.1111/bjh.13040

A. Frequency of different CNS⁺ presentations
CNS Disease	Patients, n (%)
Isolated CSF⁺	5 (33%)
Isolated PME⁺	4 (27%)
CNP⁺ & CSF⁺	3 (20%)
CNP⁺ & ICM⁺	1 (7%)
Isolated CNP⁺	2 (13%)

B. Coincidence of bone marrow and CSF positivity with other CNS findings
Disease Involvement	Patients, n (%)
BM⁺ & CNS⁺	8 (53%)
BM⁺ & CSF⁺ (± CNP)	5 (33%)
BM⁺ & isolated CSF⁺	3 (20%)
BM⁺, CSF⁺, & CNP⁺	2 (13%)
BM⁺ & CSF⁻ (+ CNP, ICM, and/or PME)	3 (20%)
BM⁺, CSF⁻, & isolated CNP⁺	1 (7%)
BM⁺, CSF⁻, CNP⁺, & ICM⁺	1 (7%)
BM⁺, CSF⁻, & isolated PME⁺	1 (7%)
BM⁻ & CNS⁺	7 (47%)
BM⁻, CSF⁺ (± CNP)	3 (20%)
BM⁻ & isolated CSF⁺	2 (13%)
BM⁻, CSF⁺, & CNP⁺	1 (7%)
BM⁻, CSF⁻, & isolated PME⁺ BM⁻, CSF⁻, & isolated CNP⁺	3 (20%) 1 (7%)

BM, bone marrow; CNS, central nervous system; CSF, cerebrospinal fluid; CNP, cranial nerve palsy; ICM, intra-cranial mass; PME, parameningeal extension.